AMGEN INC
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- AMGN [1]
- Listing exchanges
- Nasdaq [1]
- SEC industry
- Biological Products, (No Diagnostic Substances) [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- AMGEN INC [1]
- Headquarters location
- Thousand Oaks [2]
- Business address
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320 [1]
- Founded
- 1980 [2]
- Legal form
- Delaware corporation [2]
- Incorporation jurisdiction
- Delaware, United States [1]
- Official website
- www.amgen.com ↗ [2]
- Employees
- 17,900 · reported year 2014 [2]
- Annual revenue
- USD 26,323,000,000 · reported year 2022 [2]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US0311621009 [2]
- CIK
- 0000318154 [1]
- SIC code
- 2836 [1]
- Country in background record
- United States [2]
Company positioning and business
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. [3]
The company's major products are Prolia and XGEVA (denosumab) to treat osteoporosis and bone diseases ($6.6 billion in total 2025 revenues), Repatha (evolocumab) to treat hyperlipidemia ($3.0 billion in 2025 revenues), Otezla (apremilast) to treat psoriasis and psoriatic arthritis ($2.3 billion in 2025 revenues), Enbrel (etanercept) to treat autoimmune diseases ($2.2 billion in 2025 revenues), Evenity (romosozumab) to treat osteoporosis ($2.1 billion in 2025 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.9 billion in 2025 revenues), Blincyto (blinatumomab) to treat acute lymphoblastic leukemia ($1.6 billion in 2025 revenues), Nplate (romiplostim) to regulate platelet production ($1.5 billion in 2025 revenues), Tezspire (tezepelumab) to treat asthma ($1.5 billion in 2025 revenues), Kyprolis (carfilzomib) to treat cancer ($1.4 billion in 2025 revenues), Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.4 billion in 2025 revenues), Krystexxa (pegloticase) to treat gout ($1.3 billion in 2025 revenues), and Vectibix (panitumumab), a monoclonal antibody ($1.2 billion in 2025 revenues). [3]
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. [3]
Background text: Wikipedia contributors, Amgen. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Understanding company scale
Employees: 17,900 · reported year 2014. [2]
Annual revenue: USD 26,323,000,000 · reported year 2022. [2]
Financial year, securities and disclosures
The SEC submissions record gives AMGEN INC a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: AMGN (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [4]
History and key events
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2836. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was AMGEN INC founded?
Founded: 1980. The linked source provides the background record. [2]
Where is the headquarters of AMGEN INC?
Headquarters location: Thousand Oaks. The linked source provides the background record. [2]
Which business sectors are recorded for AMGEN INC?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
AMGEN INC relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — AMGEN INC filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- Wikipedia contributors — Amgen (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.